食管切除术对健康相关生活质量（HRQOL）有持久的影响。患者希望获得关于手术治疗对术后HRQOL的预期影响的详细信息。本研究旨在确定新辅助化疗和放射治疗（nCRT）和手术后短期和长期HRQOL变化的临床病理特征。 采用EORTC-QLQ-C30和QLQ-OES24问卷测量HRQOL，术前进行测量，术后三个、六个、九个和十二个月，以及术后最少六年。根据以往经验和现有文献，预先定义了几个亚组，分别针对不同的临床病理特征：基线全球HRQOL，WHO生活能力状态，组织学，肿瘤分期和肿瘤位置。本研究的主要终点是相对于基线的HRQOL维度体能功能和饮食问题的变化。次要终点包括全球HRQOL，疲劳和情绪问题。 总共有177名接受HRQOL问卷调查的患者中有134名（76％）在基线时作出了回应。相对于基线HRQOL较低的患者，报告基线全球HRQOL较高的患者在术后六年内出现了更严重的饮食问题恶化（+14.5至+18.0），全球HRQOL（-16.0至-28.0）和疲劳（+10.5至+14.9）。具有2期肿瘤（UICC第6版）的患者在饮食问题（+14.6至+19.0）和全球HRQOL（-10.1至-17.1）的恶化程度上较3期肿瘤的患者更严重。 研究结果表明，在基线条件较好的局部晚期食管癌患者中，多个HRQOL结果出现更大的下降。©2023。作者。

Esophagectomy is associated with lasting effect on health-related quality of life (HRQOL). Patients desire detailed information on the expected impact of treatment on their postoperative HRQOL. The aim of the present study is to identify clinicopathological characteristics predictive for changes in short-term and long-term HRQOL after neoadjuvant chemoradiotherapy (nCRT) and surgery.HRQOL was measured using EORTC-QLQ-C30 and QLQ-OES24 questionnaires prior to nCRT, three, six, nine and twelve months postoperatively and at a minimum of six years postoperatively. Based on previous experience and available literature, several subgroups were predefined for different clinicopathological characteristics: baseline global HRQOL, WHO performance status, histology, tumor stage and tumor location. The primary endpoints of the present study were the change compared to baseline in the HRQOL dimensions physical functioning and eating problems. Secondary endpoints were global HRQOL, fatigue and emotional problems.In total, 134 (76%) of 177 patients who received HRQOL questionnaires, responded at baseline. Patients who reported a high baseline global HRQOL had a more severe deterioration in eating problems (+14.5 to + 18.0), global HRQOL (-16.0 to -28.0) and fatigue (+10.5 to +14.9) up to six years postoperatively compared to patients who reported a low baseline global HRQOL. Patients who had stage 2 tumor (UICC 6th edition) had a more severe deterioration in eating problems (+14.6 to +19.0) and global HRQOL (-10.1 to -17.1) than patients who had stage 3 tumor.The results suggest that patients with locally advanced esophageal cancer in favorable condition at baseline decline more in terms of various HRQOL outcomes.© 2023. The Author(s).